Related Experiment Videos
Inhibition of Plasmodium falciparum malaria using antisense oligodeoxynucleotides
R H Barker1, V Metelev, E Rapaport
1Hybridon, Inc., Worcester, MA 01605, USA.
Summary
Antisense oligodeoxynucleotides (AS ODNs) show promise in inhibiting malaria parasite growth. Sequence-specific AS ODNs effectively target drug-resistant Plasmodium falciparum strains in vitro, offering a new avenue for antimalarial drug discovery.
Area of Science:
- Molecular Biology
- Parasitology
- Antimicrobial Drug Discovery
Background:
- Malaria remains a significant global health challenge, driven by drug-resistant strains of Plasmodium falciparum.
- Identifying novel drug targets is crucial for developing effective antimalarial therapies.
Purpose of the Study:
- To investigate the efficacy of antisense oligodeoxynucleotides (AS ODNs) in inhibiting the growth of drug-resistant malaria parasites.
- To evaluate the sequence-dependent activity of AS ODNs against specific Plasmodium falciparum genes.
Main Methods:
- In vitro culture of W2 and W2mef strains of drug-resistant Plasmodium falciparum.
- Treatment with various phosphorothioate (PS) AS ODNs targeting essential parasite genes.
- Assessment of parasite growth inhibition using microscopy and [3H]hypoxanthine incorporation.
Main Results:
- PS AS ODNs demonstrated target-independent growth inhibition at 1 microM.
- Significant sequence-dependent inhibition of parasite growth was observed at concentrations between 0.5 and 0.005 microM for specific AS ODNs.
- The IC50 for sequence-specific AS ODNs was approximately 0.05 microM, significantly lower than non-specific controls.
Conclusions:
- PS AS ODNs targeting specific malarial genes can significantly inhibit the growth of drug-resistant parasites in a sequence-dependent manner at sub-micromolar concentrations.
- This antisense technology presents a viable alternative for identifying novel antimalarial drug targets.